Although cancer and Parkinson disease (PD) have opposing clinical manifestations, the observation that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2), also contributes to cancer progression suggests that additional common mechanisms may be involved in the progression of both diseases more so than previously appreciated. This evidence concerns the gene UBE2E3 and cancer.